(XNCR) Xencor - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98401F1057

Stock:

Total Rating 19

Risk 33

Buy Signal -0.58

Biotechnology +2.2
Biotechnology +1.0

Market Cap: 968m
Avg Trading Vol: 6.03M USD

ATR: 6.33%
Peers RS (IBD): 29.00

Risk 5d forecast
Volatility	79.6%
Relative Tail Risk	-10.8%

Reward TTM
Sharpe Ratio	0.08
Alpha	-37.29

Character TTM
Beta	1.741
Beta Downside	2.157

Drawdowns 3y
Max DD	78.08%
CAGR/Max DD	-0.34

EPS (Earnings per Share)

EPS CAGR: -9.42%
EPS Trend: -10.1%

Last SUE: 1.60
Qual. Beats: 3

Revenue

Rev. CAGR: -25.58%
Rev. Trend: -15.8%

Last SUE: -0.15
Qual. Beats: 0

Description: XNCR Xencor

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income: -91.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.16 > 0.02 and ΔFCF/TA 6.66 > 1.0
NWC/Revenue: 401.3% < 20% (prev 405.9%; Δ -4.58% < -1%)
CFO/TA -0.15 > 3% & CFO -135.1m > Net Income -91.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.25 > 1.5 & < 3
Outstanding Shares: last quarter (74.2m) vs 12m ago 1.45% < -2%
Gross Margin: 91.62% > 18% (prev 0.50%; Δ 9112 % > 0.5%)
Asset Turnover: 13.74% > 50% (prev 12.69%; Δ 1.06% > 0%)
Interest Coverage Ratio: -1.81 > 6 (EBITDA TTM -47.2m / Interest Expense TTM 31.9m)

Altman Z'' -3.09

A: 0.58 (Total Current Assets 599.8m - Total Current Liabilities 95.9m) / Total Assets 875.5m
B: -0.91 (Retained Earnings -796.0m / Total Assets 875.5m)
C: -0.06 (EBIT TTM -57.7m / Avg Total Assets 913.7m)
D: -3.31 (Book Value of Equity -793.7m / Total Liabilities 239.9m)
Altman-Z'' Score: -3.09 = D

Beneish M -3.96

DSRI: 0.46 (Receivables 29.3m/60.8m, Revenue 125.6m/120.8m)
GMI: 0.55 (GM 91.62% / 50.18%)
AQI: 0.73 (AQ_t 0.21 / AQ_t-1 0.29)
SGI: 1.04 (Revenue 125.6m / 120.8m)
TATA: 0.05 (NI -91.9m - CFO -135.1m) / TA 875.5m)
Beneish M-Score: -3.96 (Cap -4..+1) = AAA

What is the price of XNCR shares?

As of March 01, 2026, the stock is trading at USD 12.77 with a total of 874,816 shares traded.
Over the past week, the price has changed by +11.92%, over one month by -3.04%, over three months by -26.27% and over the past year by -14.75%.

Is XNCR a buy, sell or hold?

Xencor has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XNCR.

StrongBuy: 8
Buy: 3
Hold: 0
Sell: 1
StrongSell: 0

What are the forecasts/targets for the XNCR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	28.9	126.5%
Analysts Target Price	28.9	126.5%

XNCR Fundamental Data Overview February 28, 2026

P/S = 6.4451
P/B = 1.359
Revenue TTM = 125.6m USD
EBIT TTM = -57.7m USD
EBITDA TTM = -47.2m USD
Long Term Debt = 206.0m USD (estimated: total debt 252.5m - short term 46.5m)
Short Term Debt = 46.5m USD (from shortTermDebt, last quarter)
Debt = 252.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 198.4m USD (from netDebt column, last quarter)
Enterprise Value = 784.9m USD (967.6m + Debt 252.5m - CCE 435.2m)
Interest Coverage Ratio = -1.81 (Ebit TTM -57.7m / Interest Expense TTM 31.9m)
EV/FCF = -5.68x (Enterprise Value 784.9m / FCF TTM -138.3m)
FCF Yield = -17.62% (FCF TTM -138.3m / Enterprise Value 784.9m)
FCF Margin = -110.1% (FCF TTM -138.3m / Revenue TTM 125.6m)
Net Margin = -73.20% (Net Income TTM -91.9m / Revenue TTM 125.6m)
Gross Margin = 91.62% ((Revenue TTM 125.6m - Cost of Revenue TTM 10.5m) / Revenue TTM)
Gross Margin QoQ = 90.87% (prev 87.62%)
Tobins Q-Ratio = 0.90 (Enterprise Value 784.9m / Total Assets 875.5m)
Interest Expense / Debt = 2.91% (Interest Expense 7.35m / Debt 252.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.6m (EBIT -57.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.25 (Total Current Assets 599.8m / Total Current Liabilities 95.9m)
Debt / Equity = 0.40 (Debt 252.5m / totalStockholderEquity, last quarter 635.6m)
Debt / EBITDA = -4.20 (negative EBITDA) (Net Debt 198.4m / EBITDA -47.2m)
Debt / FCF = -1.43 (negative FCF - burning cash) (Net Debt 198.4m / FCF TTM -138.3m)
Total Stockholder Equity = 630.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.06% (Net Income -91.9m / Total Assets 875.5m)
RoE = -14.58% (Net Income TTM -91.9m / Total Stockholder Equity 630.3m)
RoCE = -6.90% (EBIT -57.7m / Capital Employed (Equity 630.3m + L.T.Debt 206.0m))
RoIC = -7.25% (negative operating profit) (NOPAT -45.6m / Invested Capital 628.5m)
WACC = 10.25% (E(967.6m)/V(1.22b) * Re(12.33%) + D(252.5m)/V(1.22b) * Rd(2.91%) * (1-Tc(0.21)))
Discount Rate = 12.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.46%
[DCF] Fair Price = unknown (Cash Flow -138.3m)
EPS Correlation: -10.06 | EPS CAGR: -9.42% | SUE: 1.60 | # QB: 3
Revenue Correlation: -15.85 | Revenue CAGR: -25.58% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.69 | Chg7d=-0.059 | Chg30d=-0.059 | Revisions Net=+0 | Analysts=8
EPS current Year (2026-12-31): EPS=-2.62 | Chg7d=-0.000 | Chg30d=-0.000 | Revisions Net=+3 | Growth EPS=-111.4% | Growth Revenue=-3.6%
EPS next Year (2027-12-31): EPS=-2.75 | Chg7d=-0.440 | Chg30d=-0.440 | Revisions Net=+2 | Growth EPS=-4.8% | Growth Revenue=+27.0%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)

Additional Sources for XNCR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle